PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way

A Three‐In‐One Assembled Nanoparticle Containing Peptide–Radio‐Sensitizer Conjugate and TLR7/8 Agonist Can Initiate the Cancer‐Immunity Cycle to Trigger Antitumor Immune Response

(2022) Xueqin Zhu et al.   Small

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

(2021) Zhisong Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

A chemical conjugation of JQ ‐1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation

(2020) Xiaodong Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

(2020) Janelle C. Waite et al.   Science Translational Medicine

Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics

(2020) Emily Y. Yang et al.   Frontiers in Oncology

Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment

(2020) Anton A. A. Smith et al.   BIOMACROMOLECULES

Combination of sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7/8 agonist-based nanovaccine

(2019) Hyunjoon Kim et al.   MOLECULAR PHARMACEUTICS

The engineered anti‐GPC3 immunotoxin, HN3‐ABD‐T20, produces regression in mouse liver cancer xenografts via prolonged serum retention

(2019) Bryan D. Fleming et al.   HEPATOLOGY

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

(2019) Stefanie R. Mullins et al.   Journal for ImmunoTherapy of Cancer

Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

(2019) Katherine A. Michaelis et al.   Nature Communications

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFRT790M -Associated Drug Resistance by PD-L1 Nanobody-Mediated Codelivery

(2018) Weimin Yin et al.   Small

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

(2018) Yong Liang et al.   Nature Communications

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer

(2016) Isabel Van Audenhove et al.   EBioMedicine

Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

(2015) Jiang Zhu et al.   Journal of Hematology & Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Nanobody-based cancer therapy of solid tumors

(2015) Marta Kijanka et al.   Nanomedicine

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

(2012) Erina Koga-Yamakawa et al.   INTERNATIONAL JOURNAL OF CANCER

TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway

(2011) J. Z. Oh et al.   BLOOD

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8

(2010) D. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Human Dendritic Cells Stimulated via TLR7 and/or TLR8 Induce the Sequential Production of Il-10, IFN- , and IL-17A by Naive CD4+ T Cells

(2009) V. Lombardi et al.   JOURNAL OF IMMUNOLOGY